CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 19, 2018-- Synlogic, Inc. , (Nasdaq: SYBX ) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that preclinical data from its immuno-oncology (IO) program will...

– Expanded clinical data set from Phase 1 study confirms proof of mechanism and supports continued development of SYNB1020 for treatment of hyperammonemia – – A Phase 1b / 2a clinical trial to further evaluate SYNB1020 is open and screening patients – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- Synlogic (Nasdaq:SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present a corporate update at the Cowen and Company 38th Annual Health Care Conference at 3:30 p.m....

- Data presented at Keystone Symposium demonstrate rapid tumor rejection in preclinical models - - Data support advancement of Synthetic Biotic medicines as potential immuno-therapies for cancer - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 13, 2018-- Synlogic ( Nasdaq: SYBX ), a clinical-stage...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2018-- Synlogic (Nasdaq:SYBX) announced today that its chief medical officer, Aoife Brennan , M.B., B.Ch., and chief financial officer, Todd Shegog will present a corporate update at the Leerink Partners 7th Annual Global Healthcare Conference at 3:00...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2018-- Synlogic (Nasdaq: SYBX) , a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced it has issued an additional 769,500 shares of common stock at the public offering price of $9.75 per...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 24, 2018-- Synlogic (Nasdaq: SYBX) a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced the pricing of its underwritten public offering of 5,130,000 shares of its common stock at a public...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 23, 2018-- Synlogic (Nasdaq: SYBX) a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today announced that it has commenced an underwritten public offering of its common stock....

– Presentation of full clinical data from first in-human study of Synthetic Biotic™ medicine expected in 1Q 2018 – – IND for SYNB1020 for the treatment of hyperammonemia in patients with liver disease has been cleared by the FDA – – Additional trials in patients with UCD and PKU expected to begin...

Partnership Integrates Living Medicine Drug Discovery and Development Expertise with Leading Industrial-Scale Organism Engineering Applied to Therapeutics for the First Time Companies Aim to Expand Portfolio of Novel, Probiotic-Based, Living Medicines with Additional Partners BOSTON & CAMBRIDGE,...

- Reported Positive Top-line Results from Phase 1 Clinical Study of SYNB1020 in Healthy Volunteers - - Received Orphan Drug Designation for SYNB1618, a Synthetic Biotic TM Medicine for the Treatment of Phenylketonuria - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 13, 2017-- Synlogic, Inc....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2017-- Synlogic (Nasdaq: SYBX) announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer, will present at the following conferences in November: The Stifel 2017 Healthcare Conference at 11:45 am ET on November 15 th...